核心产品全球销售280亿，百济神州结束10年亏损长跑

Core Insights - The company achieved its first annual profit since its establishment in 2025, with total revenue of 38.205 billion yuan, a year-on-year increase of 40.4%, and a net profit of 1.422 billion yuan, reversing a loss of 4.978 billion yuan from the previous year [1][2] Financial Performance - Total revenue reached 38.205 billion yuan, up 40.4% from 27.214 billion yuan in the previous year [2] - Product revenue was 37.770 billion yuan, reflecting a 39.9% increase from 26.994 billion yuan [2] - Operating profit was 2.562 billion yuan, while total profit was 2.558 billion yuan, both transitioning from losses in the previous year [2] - Basic earnings per share improved from -3.64 yuan to 1.00 yuan [2] - The weighted average return on equity was 5.19%, recovering from -20.20% [2] Product Performance - The core product, Baiyueze® (Zebutinib), generated global sales of 28.067 billion yuan, a 48.8% increase, accounting for 73.5% of total revenue [3][5] - Sales in the U.S. market reached 20.206 billion yuan, up 45.5%, while European sales were 4.265 billion yuan, increasing by 66.4% [5] - Other product segments, including Bai Ze An® and licensed products from Amgen, contributed significantly, with total product revenue reaching 37.770 billion yuan, making up 98.9% of total revenue [6] Cash Flow and Assets - The company reported a significant increase in operating cash flow, with free cash flow reaching 9.42 billion yuan [7] - Total assets grew to 57.423 billion yuan, a 34.1% increase from the beginning of the period, while equity attributable to shareholders rose to 30.601 billion yuan, up 26.6% [7] Research and Development - R&D expenses for 2025 were 21.46 billion yuan, a 10% increase, but the proportion of R&D spending relative to revenue decreased to 40.4% [3][8] - The company has invested over 56 billion yuan in R&D since its inception, with 14.14 billion yuan spent in 2024 alone [3] Capital Structure and Shareholder Changes - Hillhouse Capital, a cornerstone investor, has reduced its stake from 8.97% to 4.89% through two rounds of share sales in 2025, cashing out approximately 7.146 billion HKD [4] - Other shareholders, including Amgen and Baker Brothers Life Sciences, maintained their holdings, while new investors have entered the shareholder base [4]